Efficacy and Safety of Rivaroxaban for Extremely Aged Patients with Venous Thromboembolism: A Retrospective, Cross-Sectional Real-World Study

References

• Kotaska A. Venous thromboembolism prophylaxis may cause more harm than benefit: an evidence-based analysis of Canadian and international guidelines. Thromb J. 2018;16:25.
   PubMed Web of Science ®Google Scholar
• Perales IJ, San Agustin K, DeAngelo J, Campbell AM. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Ann Pharmacother. 2020;54(4):344–350.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: systematic Review and Network Meta-Analysis. PLoS One. 2015;10(12):e0144856.
   PubMed Web of Science ®Google Scholar
• LeKearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• Sprynger M. Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. Rev Med Liege. 2013;68(10):548–551.
   PubMedGoogle Scholar
• Gharaibeh L, Albsoul-Younes A, Younes N. Evaluation of VTE Prophylaxis in an Educational Hospital: comparison Between the Institutional Guideline (Caprini 2006) and the ACCP Guideline (Ninth Edition). Clin App Thrombosis/Hemostasis. 2016;22(7):627–632.
   PubMed Web of Science ®Google Scholar
• Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019;30(6):897–907.
   PubMed Web of Science ®Google Scholar
• Bossaer JB, Covert KL. Direct oral anticoagulants in patients with cancer. Am J Health Syst Pharm. 2019;76(14):1019–1027.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116(2):180–187.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017;376(13):1211–1222.
   PubMed Web of Science ®Google Scholar
• Zhang X, Cai Q, Wang X, Liao K, Hu C, Chen H. Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). J Thromb Thrombolysis. 2021;52(3):863–871.
   PubMed Web of Science ®Google Scholar
• Johnson SA, Eleazer GP, Rondina MT. Pathogenesis, Diagnosis, and Treatment of Venous Thromboembolism in Older Adults. J Am Geriatr Soc. 2016;64(9):1869–1878.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(45):3145–3146.
   PubMed Web of Science ®Google Scholar
• Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost. 2008;100(5):780–788.
   PubMed Web of Science ®Google Scholar
• Roller RE, Iglseder B, Dovjak P, et al. Oral anticoagulation and risk of bleeding in elderly patients - The aspect of polypharmacy. Wiener medizinische Wochenschrift. 2010;160(11):270–275.
   PubMedGoogle Scholar
• Beyth RJ, Landefeld CS. Anticoagulants in older patients. A safety perspective. Drugs Aging. 1995;6(1):45–54.
   PubMed Web of Science ®Google Scholar
• Kooistra HA, Calf AH, Piersma-Wichers M, et al. Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists. JAMA Intern Med. 2016;176(8):1176–1183.
   PubMed Web of Science ®Google Scholar
• Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Int Med. 2000;160(4):470–478.
   PubMedGoogle Scholar
• Bauersachs RM, Herold J. Oral Anticoagulation in the Elderly and Frail. Hamostaseologie. 2020;40(1):74–83.
   PubMed Web of Science ®Google Scholar
• Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of Age. Am j Cardiol. 2019;123(12):2051–2057.
   PubMed Web of Science ®Google Scholar
• Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21.
   PubMedGoogle Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
   PubMed Web of Science ®Google Scholar
• Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112(6):2242–2247.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang C, Chen Z, et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thromb J. 2013;11(1):25.
   PubMedGoogle Scholar
• Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med. 2020;383(18):1735–1745.
   PubMed Web of Science ®Google Scholar
• Hanon O, Vidal JS, Pisica-Donose G, et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107(17):1376–1382.
   PubMed Web of Science ®Google Scholar
• Prins MH, Lensing AW. Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J. 2013;11(1):13.
   PubMedGoogle Scholar
• Ageno W, Casella IB, Chee KH, et al. Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. J Thromb Thrombolysis. 2021;51(3):561–570.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang M, Ni Y, Liang Z. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. Hematology. 2020;25(1):63–70.
   PubMed Web of Science ®Google Scholar
• Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989–1994.
   PubMed Web of Science ®Google Scholar
• Iba T, Levi M, Levy JH. Intracellular communication and immunothrombosis in sepsis. J Thromb Haemost. 2022.
   Web of Science ®Google Scholar
• Wienkamp AK, Erpenbeck L, Rossaint J. Platelets in the NETworks interweaving inflammation and thrombosis. Front Immunol. 2022;13:953129.
   PubMed Web of Science ®Google Scholar
• Boileve A, Gavaud A, Grignano E, et al. Acute and fatal cephalosporin-induced autoimmune haemolytic anaemia. Br J Clin Pharmacol. 2021;87(4):2152–2156.
   PubMed Web of Science ®Google Scholar
• Onita T, Ishihara N, Ikebuchi A, et al. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia. J Clin Pharm Ther. 2022.
   PubMed Web of Science ®Google Scholar
• Bauersachs RM, Lensing AW, Prins MH, et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014;12:25.
   PubMedGoogle Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251.
   PubMed Web of Science ®Google Scholar
• Robbins JR, Gayar OH, Zaki M, Mahan M, Buekers T, Elshaikh MA. Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer. Gynecol Oncol. 2013;131(3):593–597.
   PubMed Web of Science ®Google Scholar
• Kahl A, du Bois A, Harter P, et al. Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer. Ann Surg Oncol. 2017;24(12):3692–3699.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kang HW, Rha KH, et al. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach. J Cancer Res Clin Oncol. 2016;142(4):849–858.
   PubMed Web of Science ®Google Scholar
• Wu CC, Hsu TW, Chang CM, Yu CH, Lee CC. Age-adjusted Charlson comorbidity index scores as predictor of survival in colorectal cancer patients who underwent surgical resection and chemoradiation. Medicine. 2015;94(2):e431.
   PubMed Web of Science ®Google Scholar
• Dias-Santos D, Ferrone CR, Zheng H, Lillemoe KD, Fernández-Del Castillo C. The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. Surgery. 2015;157(5):881–887.
   PubMed Web of Science ®Google Scholar
• Liao H, Miao H, Xie P, et al. Protection of L1 nerve roots by pre-relieve tension in parallel endplate osteotomy for severe rigid thoracolumbar spine deformity. BMC Musculoskelet Disord. 2020;21(1):306.
   PubMed Web of Science ®Google Scholar
• Cai C, Tao L, Li D, et al. The prognostic value of age-adjusted Charlson comorbidity index in laparoscopic resection for hilar cholangiocarcinoma. Scand J Gastroenterol. 2024;59(3):333–343.
   PubMed Web of Science ®Google Scholar